Latest Financial Results
FY 2018
Fiscal Year Ended Dec 31, 2018
Stock Information
Company Overview
Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing innovative therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.
Investor Contact Information
Company
Rexahn Pharmaceuticals, Inc.
15245 Shady Grove Road
Suite 455
Rockville, MD 20850
Investor Relations
Transfer Agent
Olde Monmouth Stock Transfer Co., Inc.
200 Memorial Parkway
Atlantic Highlands, NJ 07716
T: 732-872-2727